Cadence Pharmaceuticals (Nasdaq: CADX) reported earnings on July 31. Here are the numbers you need to know.

The 10-second takeaway
For the quarter ended June 30 (Q2), Cadence Pharmaceuticals beat expectations on revenues and missed expectations on earnings per share.

Compared to the prior-year quarter, revenue grew significantly. GAAP loss per share dropped.

Margins expanded across the board.

Revenue details
Cadence Pharmaceuticals tallied revenue of $24.7 million. The 10 analysts polled by S&P Capital IQ expected to see sales of $23.8 million on the same basis. GAAP reported sales were much higher than the prior-year quarter's $11.1 million.

Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.

EPS details
EPS came in at -$0.14. The seven earnings estimates compiled by S&P Capital IQ averaged -$0.09 per share. GAAP EPS were -$0.14 for Q2 against -$0.25 per share for the prior-year quarter.

Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures are normalized by S&P Capital IQ and may vary to maintain comparability with normalized estimates.

Margin details
For the quarter, gross margin was 66.4%, much better than the prior-year quarter. Operating margin was -43.7%, much better than the prior-year quarter. Net margin was -48.1%, much better than the prior-year quarter. (Margins calculated in GAAP terms.)

Looking ahead
Next quarter's average estimate for revenue is $26.8 million. On the bottom line, the average EPS estimate is -$0.07.

Next year's average estimate for revenue is $104.0 million. The average EPS estimate is -$0.28.

Investor sentiment
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 70 members out of 110 rating the stock outperform, and 40 members rating it underperform. Among 31 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 19 give Cadence Pharmaceuticals a green thumbs-up, and 12 give it a red thumbs-down.

Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Cadence Pharmaceuticals is outperform, with an average price target of $7.34.